The Dyatlov Pass mystery has nothing on a mismatch repair-deficient colon tumor - both involve a scene full of clues, missing explanations, and the uncomfortable feeling that something weird happened in the dark. In this case, the mystery is why some colorectal cancers look highly visible to the immune system - practically wearing sequined jackets under a spotlight - and still manage to keep growing.
A new paper in Gut tackles that puzzle in mismatch repair-deficient, or MMRd, colorectal cancer - the subtype famous for carrying loads of mutations and often responding to immunotherapy better than many other cancers. You'd think that many mutations would make a tumor easy to spot. And sometimes it does. But tumors, being the sort of systems that fail in creative ways, have backup plans.
A cancer with too many typos
MMRd tumors have broken spell-check. Their DNA repair system - mismatch repair - normally catches copying mistakes when cells divide. When that system fails, mutations pile up fast, especially in repetitive DNA stretches called microsatellites. That is why these cancers are often called microsatellite instability-high, or MSI-H.
All those mutations can create neoantigens - new protein fragments that the immune system may recognize as foreign. In engineering terms, the tumor starts broadcasting fault signals all over the network. CD8 T cells, your body's extremely committed security team, should in theory notice and shut the thing down.
But this study shows the system has two interacting failure modes.
Immune pressure: helpful, but also weirdly selective
The researchers used a genetically engineered mouse model of MMRd colorectal cancer and compared what happened in mice with working immune systems versus mice without them. That setup let them ask a very direct question: what does immune pressure actually do to these tumors over time?
Answer: quite a lot.
In immunocompetent mice, fewer tumors developed. That is the good news. The immune system eliminated early cell clones carrying particularly immunogenic mutations - basically the loudest, most incriminating signals got removed first. This is classic immunoediting: the immune system doesn't just attack tumors, it shapes which cancer cells survive. Natural selection, but with more cytokines and worse management.
In immunodeficient mice, tumors had higher mutational burden and more genetic diversity. They also carried mutations that were absent in immunocompetent animals, and some of those mutations encoded neoantigens capable of triggering CD8 T-cell responses. In other words, without immune surveillance, the tumor genome turns into an unfiltered bug report.
That means the immune system acts like a quality-control filter. It removes the easiest-to-detect cancer clones, leaving behind the sneaky ones.
The second escape hatch: build a hostile neighborhood
If immunoediting were the whole story, the remaining tumors might just be less visible. But the paper found a second mechanism too: the tumor microenvironment itself becomes suppressive.
Tumors growing in immunocompetent hosts showed fewer cytotoxic lymphocytes and higher expression of immune checkpoint proteins. So even when immune cells are nearby, the tumor seems to lock the control panel and cut the power to the response. If your immune system is a distributed defense network, the tumor has figured out both how to reduce the alarm signal and how to jam the radios.
That dual mechanism helps explain a long-standing clinical oddity. MMRd colorectal tumors can look "immune rich" under the microscope, yet still progress. It is not that the immune system never noticed. It noticed. It just got outmaneuvered by a tumor that edited away the most obvious targets and then turned the neighborhood into a bureaucratic nightmare.
Why this matters outside the mouse cage
This is not just a neat mechanistic paper for people who enjoy reading about T cells recreationally. It has practical implications.
First, it supports the idea of neoantigen-based therapies. If some mutations create strong immune targets, we may be able to design vaccines or personalized approaches that re-teach the immune system to hit vulnerabilities the tumor cannot easily hide.
Second, it reinforces the case for immune reactivation strategies, including checkpoint blockade. MMRd colorectal cancers already have a special place in immunotherapy because many respond to PD-1 inhibitors, though not all do and some eventually resist treatment. This paper helps explain why - immune suppression inside the tumor is not some side detail, it is part of the operating manual [1,2].
Third, it reminds us that cancer is not a static lump. It is an evolving system under selection pressure. Treating it means thinking less like a sniper and more like an engineer debugging a hostile adaptive network that keeps rewriting its own code. Which, to be fair, is rude of the tumor.
The bigger picture
Recent work in colorectal cancer and cancer immunology has emphasized exactly this tension between mutation-driven visibility and immune escape [1-5]. MMRd tumors often generate plenty of targets, but target-rich environments do not guarantee victory if the surviving clones are less immunogenic and the microenvironment suppresses T-cell function.
That has consequences for patient care. Better biomarkers may need to capture not just mutation burden, but also which mutations remain, whether they encode usable neoantigens, and whether the local immune circuitry is actually online. Counting immune cells alone may be like checking whether a server room has staff in it while ignoring the fact that somebody unplugged the routers.
This study gives that paradox a cleaner explanation: MMRd colorectal tumors escape by combining genetic camouflage with local immune shutdown. Not elegant, exactly. More like malware with decent customer support. But now that we can see the playbook more clearly, we get a better shot at breaking it.
References
-
Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409-413. doi:10.1126/science.aan6733
-
Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361-375. doi:10.1038/s41575-019-0126-x
-
Mlecnik B, Bifulco C, Bindea G, et al. Multicenter International Society for Immunotherapy of Cancer study of the Immunoscore assay for prognosis in colon cancer. J Clin Oncol. 2020;38(31):3638-3651. doi:10.1200/JCO.19.03200
-
Overman MJ, Ernstoff MS, Morse MA. Where we stand with immunotherapy in colorectal cancer: facts and hopes. Clin Cancer Res. 2022;28(1):35-46. doi:10.1158/1078-0432.CCR-21-1332
-
Xiao Y, Freeman GJ. The microsatellite instability subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov. 2022;12(6):1389-1391. doi:10.1158/2159-8290.CD-22-0369
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.